These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31757859)

  • 1. Interventions for Occluded Central Venous Catheters: A Meta-analysis.
    da Costa ACC; Vieira NNP; Vasques CI; Ferreira EB; Guerra ENS; Dos Reis PED
    Pediatrics; 2019 Dec; 144(6):. PubMed ID: 31757859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
    Clase CM; Crowther MA; Ingram AJ; Cinà CS
    J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer.
    Schoot RA; van Dalen EC; van Ommen CH; van de Wetering MD
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008975. PubMed ID: 23799867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis.
    da Costa ACC; Ribeiro JM; Vasques CI; De Luca Canto G; Porporatti AL; Dos Reis PED
    Support Care Cancer; 2019 Feb; 27(2):407-421. PubMed ID: 30370471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for restoring patency of occluded central venous catheter lumens (Review).
    van Miert C; Hill R; Jones L
    Evid Based Child Health; 2013 Mar; 8(2):695–749. PubMed ID: 24482900
    [No Abstract]   [Full Text] [Related]  

  • 9. Restoring patency of occluded central venous catheters.
    Hurtubise MR; Bottino JC; Lawson M; McCredie KB
    Arch Surg; 1980 Feb; 115(2):212-3. PubMed ID: 7356837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urokinase lock-therapy for hemodialysis occluded central venous catheters.
    Li Cavoli G; Schillaci O; Zagarrigo C; Servillo F; Li Cavoli TV; Palmeri M; Rotolo U
    Blood Purif; 2015; 39(1-3):238. PubMed ID: 25823425
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of obstruction and thrombosis due to central venous catheterization].
    Leititis JU
    Klin Padiatr; 1991; 203(6):420-3. PubMed ID: 1758144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters.
    Atkinson JB; Bagnall HA; Gomperts E
    JPEN J Parenter Enteral Nutr; 1990; 14(3):310-1. PubMed ID: 2112648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
    Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion: A Patient-Level Meta-analysis.
    Schrag M; Youn T; Schindler J; Kirshner H; Greer D
    JAMA Neurol; 2015 Oct; 72(10):1148-54. PubMed ID: 26258861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter.
    Orgeron GM; Pollard JL; Pourmalek P; Sloane PJ
    Pharmacotherapy; 2015 Oct; 35(10):e153-8. PubMed ID: 26497485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
    Eyrich H; Walton T; Macon EJ; Howe A
    Am J Health Syst Pharm; 2002 Aug; 59(15):1437-40. PubMed ID: 12166043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.